AI Model Shows Promise in Predicting Cognitive Decline Among MS Patients
A machine learning model developed by researchers at the University of California, San Francisco (UCSF), may help identify early signs of cognitive decline in individuals with multiple sclerosis (MS), according to a study published in *Neurology* in September 2024. The algorithm analyzed medical data from over 1,200 MS patients, including brain scans and clinical assessments, to detect patterns linked to worsening memory and processing speed.
How the AI Model Works
The model uses a combination of structural MRI scans and patient-reported symptoms to predict cognitive decline up to two years in advance. Researchers trained the algorithm on data from the National MS Society’s longitudinal study, which tracks disease progression. The system identified specific changes in brain volume and white matter integrity as key indicators. “This tool could allow clinicians to intervene earlier, potentially slowing cognitive deterioration,” said Dr. Emily Chen, a neurologist at UCSF and co-author of the study.
Implications for MS Patients
Cognitive impairment affects up to 65% of people with MS, yet early detection remains challenging. Traditional methods rely on subjective assessments, while the new model provides a quantitative risk score. The study’s lead author, Dr. Raj Patel, noted that the AI could help personalize treatment plans. “Patients flagged as high-risk might benefit from targeted therapies, such as cognitive rehabilitation or disease-modifying drugs,” he said.
Limitations and Next Steps
While the findings are promising, experts caution that the model requires further validation. The study’s sample was predominantly white and middle-aged, raising questions about its applicability to diverse populations. The National MS Society has called for larger, more inclusive trials. “We need to ensure this technology works across all demographics before it can be widely adopted,” said Dr. Lisa Nguyen, a clinical professor at Columbia University.
What’s Next for AI in MS Research?
The study adds to growing interest in AI’s role in neurological diseases. In 2023, a similar algorithm developed by the Mayo Clinic predicted Alzheimer’s risk with 89% accuracy. However, experts emphasize that AI should complement, not replace, clinical judgment. “These tools are only as good as the data they’re trained on,” said Dr. Sarah Mitchell, a bioethicist at Harvard Medical School. “Transparency and ongoing oversight are critical.”
For now, the UCSF team plans to refine the model using data from the European MS Registry, with results expected by 2025. Patients and clinicians are advised to consult healthcare providers for personalized care options.